Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3944]

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )

Balancing innovation and Common Sense In Oncology (CSO)

Prof Richard Sullivan - King's College London, UK

Balancing innovation and Common Sense In Oncology (CSO) ( Prof Richard Sullivan - King's College London, UK )

2 year recurrence free survival benefit for resectable melanoma treated with...

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...

Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )

Atezolizumab with platinum-based CT and niraparib show no improvement in...

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK

Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS...

Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

More from ecancer